Literature DB >> 24684874

Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Elizabeth Ann L Enninga1, Shernan G Holtan2, Douglas J Creedon3, Roxana S Dronca4, Wendy K Nevala4, Simona Ognjanovic1, Svetomir N Markovic5.   

Abstract

Similarities between the pathologic progression of cancer and the physiologic process of placentation (eg, proliferation, invasion, and local/systemic tolerance) have been recognized for many years. Sex hormones such as human chorionic gonadotropin, estrogens, progesterone, and others contribute to induction of immunologic tolerance at the beginning of gestation. Sex hormones have been shown to play contributory roles in the growth of cancers such as breast cancer, prostrate cancer, endometrial cancer, and ovarian cancer, but their involvement as putative mediators of the immunologic escape of cancer is still being elucidated. Herein, we compare the emerging mechanism by which sex hormones modulate systemic immunity in pregnancy and their potentially similar role in cancer. To do this, we conducted a PubMed search using combinations of the following keywords: "immune regulation," "sex hormones," "pregnancy," "melanoma," and "cancer." We did not limit our search to specific publication dates. Mimicking the maternal immune response to pregnancy, especially in late gestation, might aid in design of better therapies to reconstitute endogenous antitumor immunity and improve survival.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684874      PMCID: PMC4286150          DOI: 10.1016/j.mayocp.2014.01.006

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  189 in total

Review 1.  The role of hCG in reproductive medicine.

Authors:  S D Keay; M Vatish; E Karteris; E W Hillhouse; H S Randeva
Journal:  BJOG       Date:  2004-11       Impact factor: 6.531

2.  Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis.

Authors:  J L Shifren; J F Tseng; C J Zaloudek; I P Ryan; Y G Meng; N Ferrara; R B Jaffe; R N Taylor
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

3.  A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin.

Authors:  Andrzej Slominski; Jordan Zjawiony; Jacobo Wortsman; Igor Semak; Jeremy Stewart; Alexander Pisarchik; Trevor Sweatman; Josep Marcos; Chuck Dunbar; Robert C Tuckey
Journal:  Eur J Biochem       Date:  2004-11

4.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

5.  Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium.

Authors:  Sam Mesiano; Eng-Cheng Chan; John T Fitter; Kenneth Kwek; George Yeo; Roger Smith
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

6.  Modulation of cell growth and apoptosis by sex hormones in cultured monocytic THP-1 cells.

Authors:  Maurizio Cutolo; Alberto Sulli; Chiara Craviotto; Lamberto Felli; Carmen Pizzorni; Bruno Seriolo; Barbara Villaggio
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

7.  Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers.

Authors:  Anna Eriksson; Renhai Cao; Robert Pawliuk; Sanna Maria Berg; Monica Tsang; Danielle Zhou; Christina Fleet; Katerina Tritsaris; Steen Dissing; Philippe Leboulch; Yihai Cao
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

8.  CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine 2,3-dioxygenase.

Authors:  Weihong Li; Bin Li; Wei Fan; Lihong Geng; Xiaohong Li; Lei Li; Zhongying Huang; Shangwei Li
Journal:  J Reprod Immunol       Date:  2009-04-11       Impact factor: 4.054

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study.

Authors:  Vincenzo de Giorgi; Carmelo Mavilia; Daniela Massi; Alessia Gozzini; Palma Aragona; Annalisa Tanini; Serena Sestini; Milena Paglierani; Vieri Boddi; Maria Luisa Brandi; Torello Lotti
Journal:  Arch Dermatol       Date:  2009-01
View more
  25 in total

1.  Melanoma resistance: a bright future for academicians and a challenge for patient advocates.

Authors:  Andrzej T Slominski; J Andrew Carlson
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 2.  Current position of TNF-α in melanomagenesis.

Authors:  Iuliana Nenu; Diana Tudor; Adriana Gabriela Filip; Ioana Baldea
Journal:  Tumour Biol       Date:  2015-08-18

3.  Maternal T Cells in the Human Placental Villi Support an Allograft Response during Noninfectious Villitis.

Authors:  Elizabeth Ann L Enninga; Patrick Raber; Reade A Quinton; Rodrigo Ruano; Nadia Ikumi; Clive M Gray; Erica L Johnson; Rana Chakraborty; Sarah E Kerr
Journal:  J Immunol       Date:  2020-04-22       Impact factor: 5.422

4.  Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract.

Authors:  Zheng Shen; Marta Rodriguez-Garcia; Mickey V Patel; Fiona D Barr; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2016-06-19       Impact factor: 3.886

Review 5.  Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma.

Authors:  Nico Buettner; Robert Thimme
Journal:  Semin Immunopathol       Date:  2018-11-29       Impact factor: 9.623

Review 6.  Sex Drives Dimorphic Immune Responses to Viral Infections.

Authors:  Soumitra Ghosh; Robyn S Klein
Journal:  J Immunol       Date:  2017-03-01       Impact factor: 5.422

7.  Conjunctival Melanoma during Pregnancy.

Authors:  Rana'a T Al-Jamal; Hardeep Singh Mudhar; Zanna Currie; Ian G Rennie; Sachin M Salvi
Journal:  Ocul Oncol Pathol       Date:  2016-11-08

8.  Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.

Authors:  Elizabeth Ann L Enninga; Wendy K Nevala; Shernan G Holtan; Alexey A Leontovich; Svetomir N Markovic
Journal:  Melanoma Res       Date:  2016-10       Impact factor: 3.599

9.  Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapies.

Authors:  Jessica R Walter; Shuai Xu; Amy S Paller; Jennifer N Choi; Teresa K Woodruff
Journal:  J Am Acad Dermatol       Date:  2016-09       Impact factor: 11.527

10.  Upregulation of HLA-Class I and II in Placentas Diagnosed with Villitis of Unknown Etiology.

Authors:  Elizabeth Ann L Enninga; Alexey A Leontovich; Bohdana Fedyshyn; Laurie Wakefield; Manish Gandhi; Svetomir N Markovic; Rodrigo Ruano; Sarah E Kerr
Journal:  Reprod Sci       Date:  2020-01-06       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.